Clinical trials: Benign Hyperplasia of Prostate
Benign Prostatic Hyperplasia
A Study in Men With Benign Prostatic Hyperplasia
The purpose of the study is to determine whether LY500307 helps symptoms of Benign Prostatic Hyperplasia (BPH)
- Trial name
- NCT01097707
- Testing
- LY500307
- Where
- 70 sites in United States, Australia and 6 more
- Volunteers
- 414 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia (BPH)
China Greenlight Registry Study (Post-market)
The duration of the study is expected to take approximately 3 years, which includes a recruitment period of approximately 12-months and 2 years (24-months) to complete procedure and follow-up visits.
- Trial name
- NCT03736512
- Testing
- GreenLight XPS™ 532 nm Laser System with MoXy™ laser fiber
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hyperplasia
Α Prospective Observational Study for the Evaluation of Disease Control and Quality of Life in Patients With Benign PROStatic hyPERplasia Under Fixed Dose combΙnaTion Treatment With Dutasteride and Tamsulosin . PROSPERITY Group of Studies (I&II)
Investigation of the efficacy and safety of the stable combination of dutasteride and tamsulosin (Dinaplex®) in the Greek population as well as the evaluation of the quality of life of patients with benign prostatic hyperplasia…
- Trial name
- PROSPERITY (NCT04831476)
- Testing
- Patients with Benign Prostate Hyperplasia
- Where
- Greece
- Volunteers
- 1,296 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Benign Prostate Hyperplasia
A Study to Evaluate the Efficacy and Safety of ASP4901 in Patients With Benign Prostate Hyperplasia
The purpose of this study is to compare the efficacy of ASP4901 with placebo in patients with benign prostatic hyperplasia. The safety and tolerability of ASP4901 will also be evaluated.
- Trial name
- NCT02038868
- Testing
- ASP4901, Tamsulosin
- Where
- 2 sites in Japan
- Volunteers
- 320 people
- Sponsor
- Astellas Pharma Inc
Benign Prostatic Hyperplasia
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules
The main objective of this study is to evaluate efficacy and safety of HCP1301 capsule in patients with Benign Prostatic Hyperplasia and Erectile Dysfunction
- Trial name
- NCT02667938
- Testing
- HCP1303 capsule 5/0.2mg, HCP1303 capsule 5/0.4mg, HGP1201
- Volunteers
- 510 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH
Clinical Trial to Compare the Efficacy and Safety of Solifenacin/Tamsulosin Combination Therapy with Tamsulosin Monotherapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
- Trial name
- NCT02972268
- Testing
- Tamsulosin 0.2mg + Solifenacin 5mg
- Where
- South Korea
- Volunteers
- 780 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Prostatic Hyperplasia
Dutasteride (GI198745) In Benign Prostatic Hyperplasia Subjects
This study will assess the efficacy and safety of GI198745 0.5mg given once daily for 52 weeks to Benign Prostatic Hyperplasia (BPH) patients.
- Trial name
- NCT00368979
- Testing
- Dutasteride
- Where
- 26 sites in Japan
- Volunteers
- 378 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
A Clinical Trial to Evaluate the Bioequivalence of AD-116A Compared to AD-1161 in Healthy Adult Male Volunteers
The study compare and evaluate the bioequivalence between the administration of AD-116A and the administration of AD-1161 in healthy adult male volunteers
- Trial name
- NCT07715305
- Testing
- AD-116A, AD-1161
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Benign Prostatic Hyperplasia
Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
The purpose of this trial is to evaluate the dose response relationship of lonidamine and the primary efficacy endpoint, International Prostate Symptom Score (IPSS), in subjects with symptomatic benign prostatic hyperplasia (BPH).
- Trial name
- NCT00237536
- Testing
- Lonidamine
- Where
- 34 sites in United States
- Volunteers
- 240 people
- Sponsor
- Threshold Pharmaceuticals
Bladder Cancer
Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection
RATIONALE: Transurethral resection is a less invasive type of surgery for bladder cancer or benign prostatic hyperplasia. Transurethral resection using a loop resectoscope may have fewer side effects and improve recovery.
- Trial name
- NCT00303654
- Testing
- biopsy, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Roei Medical Technologies Ltd.
BPH (Benign Prostatic Hyperplasia)
RT-310 Safety and Feasibility BPH Study
RT-310, is intended to deliver drug locally to the prostate gland for the management of prostate disease, while minimizing systemic exposure and its associated side-effects.
- Trial name
- NCT07264205
- Testing
- RT-310
- Where
- Dominican Republic
- Volunteers
- 20 people
- Sponsor
- Resurge Therapeutics Inc.
Benign Prostate Hyperplasia
Safety and Pharmacokinetic Interaction Study of Tadalafil and Dutasteride
This is an open-label, two-arm, one-sequence, cross-over study to evaluate the safety and pharmacokinetic interaction after oral concomitant administration of tadalafil and dutasteride in healthy male volunteers.
- Trial name
- NCT01942551
- Testing
- Tadalafil, Dutasteride
- Where
- South Korea
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Dongkook Pharmaceutical Co., Ltd.
Benign Prostatic Hyperplasia
The Zenflow Spring System Safety, Performance and Effectiveness Study
This is a clinical evaluation to assess the safety and performance of the Zenflow Spring System when used as intended to relieve symptoms of obstructive Benign Prostatic Hyperplasia (BPH).
- Trial name
- ZEST2 (NCT03595735)
- Testing
- Zenflow Spring System
- Where
- 3 sites in Mexico
- Volunteers
- 40 people
- Sponsor
- Zenflow, Inc.
Benign Prostatic Hyperplasia
Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia
The purpose of this study is to assess the safety and effectiveness of S-equol in men with benign prostatic hyperplasia.
- Trial name
- NCT00962390
- Testing
- S-equol
- Where
- 15 sites in United States, India
- Volunteers
- 116 people
- Sponsor
- Ausio Pharmaceuticals, LLC
LUTS, Benign Prostatic Hyperplasia
Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin
The purpose of this study is to investigate the pharmacokinetic drug interaction between Solifenacin and Tamsulosin in healthy male volunteers.
- Conditions
- LUTS, Benign Prostatic Hyperplasia, Overactive Bladder
- Trial name
- NCT02180997
- Testing
- Tamsulosin, Solifenacin, Tamsulosin and solifenacin
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Neuflo System for the Treatment of BPH
The goal of this clinical study is to assess the effectiveness and safety of the Neuflo System for the treatment of benign prostatic hyperplasia (BPH).
- Trial name
- NCT05884580
- Testing
- Neuflo BPH Treatment System
- Where
- New Zealand
- Volunteers
- 1 people
- Sponsor
- ProstaCare Pty Ltd
Healthy
Pharmacokinetics of MCS in Healthy Volunteers
This study is to examine the pharmacokinetics, absorption and serum concentrations of MCS and other components after once-daily oral dosing of MCS.
- Trial name
- MCS-2-US-pk (NCT01003171)
- Testing
- MCS-2 soft-gel capsule
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
Benign Prostatic Hypertrophy
Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Benign Prostatic Hypertrophy (BPH) is a common and bothersome condition of aging men. It is characterized by an enlargement of the prostate occurring in human male over the age of 50 which increases in prevalence with age, and…
- Trial name
- NCT00663858
- Testing
- Cetrorelix 78+78
- Where
- 54 sites in Belarus, Bulgaria and 8 more
- Volunteers
- 420 people
- Sponsor
- AEterna Zentaris
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
A Randomized Triple-Blind Placebo-Controlled Study to Evaluate the Effects of a Supplement on Lower Urinary Tract Symptoms in Men.
This study aims to evaluate the effects of the ProstaThrive™ supplement on lower urinary tract symptoms (LUTS) in men. It is a 90-day virtual, randomized, placebo-controlled trial with 80 male participants aged 40 and above.
- Conditions
- Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, Erectile Dysfunction
- Trial name
- NCT06504472
- Testing
- ProstaThrive™ Supplement
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Optimale
Benign Prostatic Hyperplasia
The Zenflow Spring System Safety and Performance Study (ZEST CAN)
The objectives of the trial are to demonstrate the safety and performance of the Zenflow Spring System in relieving the symptoms of obstructive Benign Prostatic Hyperplasia (BPH).
- Trial name
- NCT04309695
- Testing
- Zenflow Spring System
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Zenflow, Inc.